Edition:
United States

Hemispherx Biopharma Inc (HEB.A)

HEB.A on American Stock Exchange

0.49USD
4:02pm EDT
Change (% chg)

$-0.00 (-1.02%)
Prev Close
$0.49
Open
$0.50
Day's High
$0.50
Day's Low
$0.48
Volume
4,365
Avg. Vol
21,170
52-wk High
$2.63
52-wk Low
$0.40

HEB.A

Chart for HEB.A

About

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development... (more)
No analyst recommendations are available for HEB.A.

Overall

Beta: -0.64
Market Cap(Mil.): $13.03
Shares Outstanding(Mil.): 26.59
Dividend: --
Yield (%): --

Financials

  HEB.A Industry Sector
P/E (TTM): -- 246.80 19.12
EPS (TTM): -0.35 -- --
ROI: -50.00 -7.96 -5.05
ROE: -52.04 -10.57 -4.29

BRIEF-Hemispherx Biopharma announces quarterly loss per share $0.11

* Hemispherx Biopharma announces financial results for the three months ended March 31, 2017

May 15 2017

BRIEF-Hemispherx Biopharma says order of newly manufactured Rintatolimod has been shipped

* Hemispherx Biopharma Inc says order of newly manufactured Rintatolimod for sale utilizing early access program in Europe has been shipped Source text for Eikon: Further company coverage:

Jan 26 2017

BRIEF-Hemispherx Biopharma enters into purchase order with Jubilant Hollister Stier

* Hemispherx Biopharma- On Jan. 3, entered into purchase order with Jubilant Hollister Stier, where Jubilant will manufacture commercial batch of Ampligen for co Source: (http://bit.ly/2ju230U) Further company coverage:

Jan 17 2017

BRIEF-Hemispherx Biopharma announces extension of Rintatolimod European early access program

* Hemispherx Biopharma announces extension of Rintatolimod European early access program (eap) to pancreatic cancer patients Source text for Eikon: Further company coverage:

Jan 11 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.70 -0.10
Pfizer Inc. (PFE.N) $34.17 +0.11
Merck & Co., Inc. (MRK.N) $66.16 +0.14
GlaxoSmithKline plc (GSK.L) 1,708.50 -13.50
AstraZeneca plc (AZN.L) 5,401.00 -107.00
Baxter International Inc (BAX.N) $61.38 +0.70
MediGene AG (MDG1k.DE) €11.61 -0.09

Earnings vs. Estimates